Hangzhou Biotest Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	448.37	519.74	435.93	1,894	1,811
Other Revenue	-	39.67	6.18	7.23	7.09
Revenue	448.37	559.4	442.11	1,901	1,818
Revenue Growth (YoY)	-19.85%	26.53%	-76.74%	4.57%	110.09%
Cost of Revenue	-	286.6	269.6	940.21	705.47
Gross Profit	448.37	272.81	172.51	960.93	1,113
Selling, General & Admin	-	85.9	79.21	86.09	69.63
Research & Development	-	63.57	80.48	108.21	61.92
Other Operating Expenses	398.32	7.05	4.95	19.49	16.84
Operating Expenses	398.32	160.05	168.31	208.2	151.61
Operating Income	50.05	112.76	4.21	752.73	961
Interest Expense	-	-0.03	-0.14	-0.19	-0.68
Interest & Investment Income	-	57.28	76.9	51.91	15.36
Currency Exchange Gain (Loss)	-	11.44	13.07	111.92	-15.48
Other Non Operating Income (Expenses)	-0.85	-1.92	-0.59	-1.1	-0.87
EBT Excluding Unusual Items	49.2	179.52	93.46	915.26	959.34
Gain (Loss) on Sale of Investments	-	0.26	-	0.06	0.84
Gain (Loss) on Sale of Assets	-	-0.33	0	-	-
Asset Writedown	-	-	-6.35	-18.78	-0
Other Unusual Items	-	15.47	28.77	5.35	8.45
Pretax Income	49.2	194.92	115.88	901.9	968.63
Income Tax Expense	2.41	28.14	10.58	128.33	132.87
Earnings From Continuing Operations	46.8	166.78	105.3	773.56	835.76
Minority Interest in Earnings	-	2.74	1.31	0.07	-2.17
Net Income	46.8	169.52	106.61	773.63	833.59
Net Income to Common	46.8	169.52	106.61	773.63	833.59
Net Income Growth	-72.39%	59.01%	-86.22%	-7.19%	91.56%
Shares Outstanding (Basic)	146	147	149	149	121
Shares Outstanding (Diluted)	146	147	149	149	121
Shares Change (YoY)	-0.79%	-1.23%	-0.10%	23.14%	8.33%
EPS (Basic)	0.32	1.15	0.71	5.18	6.87
EPS (Diluted)	0.32	1.15	0.71	5.18	6.87
EPS Growth	-72.17%	61.00%	-86.21%	-24.64%	76.84%
Free Cash Flow	-	-116.23	74.96	524.29	707.92
Free Cash Flow Per Share	-	-0.79	0.50	3.51	5.84
Dividend Per Share	-	1.071	0.571	1.571	2.143
Dividend Growth	-	87.50%	-63.64%	-26.67%	-
Gross Margin	100.00%	48.77%	39.02%	50.54%	61.20%
Operating Margin	11.16%	20.16%	0.95%	39.59%	52.86%
Profit Margin	10.44%	30.30%	24.11%	40.69%	45.85%
Free Cash Flow Margin	-	-20.78%	16.95%	27.58%	38.94%
EBITDA	71.32	134.03	28.88	772.63	969.2
EBITDA Margin	15.91%	23.96%	6.53%	40.64%	53.31%
D&A For EBITDA	21.27	21.27	24.68	19.9	8.2
EBIT	50.05	112.76	4.21	752.73	961
EBIT Margin	11.16%	20.16%	0.95%	39.59%	52.86%
Effective Tax Rate	4.90%	14.44%	9.13%	14.23%	13.72%
Revenue as Reported	-	559.4	442.11	1,901	1,818
Advertising Expenses	-	2.82	4.21	3.19	1.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.